CrystecPharma opens R&D facility in Haimen City, China
Facility will support UK-based crystal and particle engineering specialist's existing Chinese subsidiary to expand product development services
CrystecPharma has opened a new research and development facility in Haimen City, Jiangsu Province, China, the UK-based pharmaceutical development firm said Wednesday.
The new facility at Haimen Science and Technology Park was established after Crystec participated in the Yangtze Delta Advanced Drug Development platform, jointly funded by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and the Haimen government.
The platform, which has received GBP 550 million equivalent in investment, is dedicated to accelerating pharmaceutical product innovation underpinned by pharmaceutical excipients and drug delivery technologies.
Crystec said its proprietary mSAS supercritical fluid technology will play a key role in enabling the development of new therapeutics, creation of value-added medicines, and in simplification of formulations and manufacturing processes.
“This cutting-edge research facility will enhance our capacity to support clients across China and the rest of the world, and will provide opportunities to achieve rapid transition from proof of concept studies to delivering clinical material for human trials in China,” said Dr. Qun Shao, Crystec’s Chief Operations Officer.
The new Haimen facility will support Crystec’s ongoing development strategy in China, working alongside Crystec’s existing China subsidiary, Tianjin Crystec Pharmaceutical Technology, and its UK headquarters in Bradford, UK, to expand and enhance product development services offered across the region and globally.
Related News
-
News Biotheus partners with BioNTech to take their anti-tumour therapy global
Innovative biotech company Biotheus has signed a deal with BioNTech to manufacture, market, and distribute their latest anti-tumour therapy around the world. -
News Roche acquires rights to Zion Pharma's HER2-positive breast cancer therapeutic
Roche launches into a new agreement with Zion Pharma, a leading Chinese pharmaceutical company, to help develop and commercialise their flagship small molecule tyrosine kinase inhibitor, ZN-A-1041. -
News 2023 Lunar New Year Round-up: Biopharma in the APAC region
With the Lunar New Year ushering in celebrations for the pharmaceutical community around the world on Sunday January 22, 2023, we’ve rounded up some of the top CPHI Online articles and reports from the last year looking at pharmaceutical markets ... -
News Lonza start commercial operations in newly expanded facility
Lonza Small Molecules adds new capabilities to their expanded facility in China, enabling smoother transitions between small and large scale manufacturing. -
News Thermo Fisher Scientific expands with state-of-the-art facility in China
Thermo Fisher Scientific are to open a new cGMP facility in China, including the latest technology so that they can assist in the accelerated provision of medicines to patients. -
News Chinese market represents ‘single greatest generational opportunity’ for Pharma
China’s pharmaceutical industry is changing from formerly generics-focused into one that emphasizes innovation, spurred by shifting government policy and an aging population. -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News WuXi STA launches new HPAPI production facility in China
The new plant features flow chemistry and milling technology, as well as reactors up to 3,000 liters
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance